Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2018, Article ID 8578051, 12 pages
https://doi.org/10.1155/2018/8578051
Research Article

Restoring Inflammatory Mediator Balance after Sofosbuvir-Induced Viral Clearance in Patients with Chronic Hepatitis C

1Laboratório Multiusuário de Apoio à Pesquisa em Nefrologia e Ciências Médicas, Faculdade de Medicina, Hospital Universitário Antônio Pedro, Universidade Federal Fluminense, Niterói, Brazil
2Laboratório de Ultraestrutura Celular Hertha Meyer, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
3Departamento de Patologia, Faculdade de Medicina, Universidade Federal Fluminense, Niterói, Brazil
4Centro de Referência de Tratamento em Hepatites/HUAP, Serviço de Gastroenterologia, Departamento de Medicina Clínica, Faculdade de Medicina, Universidade Federal Fluminense, Niterói, Brazil
5Laboratório de Imunologia Viral, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brazil
6Department of Microbiology, Infectiology and Immunology, Centre de Recherche du CHUM, Université de Montréal, Montreal, Canada

Correspondence should be addressed to Elzinandes Leal de Azeredo; rb.zurcoif.coi@sednanizle and Andrea Alice Silva; rb.ffu.di@avlisaa

Received 20 December 2017; Accepted 26 March 2018; Published 27 May 2018

Academic Editor: Anshu Agrawal

Copyright © 2018 Geórgia Nascimento Saraiva et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. World Health Organization (WHO), Global Hepatitis Report 2017, World Health Organization, Geneva, Switzerland, 2017, Licence: CC BY-NC-SA 3.0 IGO.
  2. Brazil, Ministry of Health, Clinical Protocol and Therapeutic Guidance for Hepatitis C and Coinfections, Conitec, Brasilia, Brasil, 2017.
  3. K. Kumthip and N. Maneekarn, “The role of HCV proteins on treatment outcomes,” Virology Journal, vol. 12, no. 1, p. 217, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Medeiros, C. de Morais Salviato, N. F. do Rosário et al., “Adverse effects of direct acting antiviral-based regimens in chronic hepatitis C patients: a Brazilian experience,” International Journal of Clinical Pharmacy, vol. 39, no. 6, pp. 1304–1311, 2017. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Duffy, R. Mamdouh, M. Laird et al., “The ABCs of viral hepatitis that define biomarker signatures of acute viral hepatitis,” Hepatology, vol. 59, no. 4, pp. 1273–1282, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. M.-T. Wong and S. S.-L. Chen, “Emerging roles of interferon-stimulated genes in the innate immune response to hepatitis C virus infection,” Cellular & Molecular Immunology, vol. 13, no. 1, pp. 11–35, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. F. C. Paquissi, “Immunity and fibrogenesis: the role of Th17/IL-17 axis in HBV and HCV-induced chronic hepatitis and progression to cirrhosis,” Frontiers in Immunology, vol. 8, 2017. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. Tao, M. Wang, E. Chen, and H. Tang, “Liver regeneration: analysis of the main relevant signaling molecules,” Mediators of Inflammation, vol. 2017, Article ID 4256352, 9 pages, 2017. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Costantini, F. Capone, E. Guerriero, P. Maio, G. Colonna, and G. Castello, “Serum cytokine levels as putative prognostic markers in the progression of chronic HCV hepatitis to cirrhosis,” European Cytokine Network, vol. 21, no. 4, pp. 251–256, 2010. View at Google Scholar
  10. P. Fallahi, C. Ferri, S. M. Ferrari, A. Corrado, D. Sansonno, and A. Antonelli, “Cytokines and HCV-related disorders,” Clinical and Developmental Immunology, vol. 2012, article 468107, 10 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Hengst, C. S. Falk, V. Schlaphoff et al., “Direct-acting antiviral–induced hepatitis C virus clearance does not completely restore the altered cytokine and chemokine milieu in patients with chronic hepatitis C,” Journal of Infectious Diseases, vol. 214, no. 12, pp. 1965–1974, 2016. View at Publisher · View at Google Scholar · View at Scopus
  12. D. Baskic, V. R. Vukovic, S. Popovic et al., “Cytokine profile in chronic hepatitis C: an observation,” Cytokine, vol. 96, pp. 185–188, 2017. View at Publisher · View at Google Scholar · View at Scopus
  13. M. L. Shiffman, R. K. Sterling, M. Contos et al., “Long term changes in liver histology following treatment of chronic hepatitis C virus,” Annals of Hepatology, vol. 13, no. 4, pp. 340–349, 2014. View at Google Scholar
  14. J. Chan, N. Gogela, H. Zheng et al., “Direct-acting antiviral therapy for chronic HCV infection results in liver stiffness regression over 12 months post-treatment,” Digestive Diseases and Sciences, vol. 63, no. 2, pp. 486–492, 2018. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Facciorusso, V. Del Prete, A. Turco, R. V. Buccino, M. C. Nacchiero, and N. Muscatiello, “Long-term liver stiffness assessment in hepatitis C virus patients undergoing antiviral therapy: results from a 5-year cohort study,” Journal of Gastroenterology and Hepatology, vol. 33, no. 4, pp. 942–949, 2018. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Florholmen, M. G. Kristiansen, S. E. Steigen et al., “A rapid chemokine response of macrophage inflammatory protein (MIP)-1α, MIP-1β and the regulated on activation, normal T expressed and secreted chemokine is associated with a sustained virological response in the treatment of chronic hepatitis C,” Clinical Microbiology and Infection, vol. 17, no. 2, pp. 204–209, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. G. Par, L. Szereday, T. Berki et al., “Increased baseline proinflammatory cytokine production in chronic hepatitis C patients with rapid virological response to peginterferon plus ribavirin,” PLoS One, vol. 8, no. 7, article e67770, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. Z. Q. Han, T. Huang, Y. Z. Deng, and G. Z. Zhu, “Expression profile and kinetics of cytokines and chemokines in patients with chronic hepatitis C,” International Journal Clinical and Experimental Medicine, vol. 8, no. 10, pp. 17995–18003, 2015. View at Google Scholar
  19. M. K. Jain, B. Adams-Huet, D. Terekhova et al., “Acute and chronic immune biomarker changes during interferon/ribavirin treatment in HIV/HCV co-infected patients,” Journal of Viral Hepatitis, vol. 22, no. 1, pp. 25–36, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. E. G. Menezes, J. G. A. Coelho-dos-Reis, L. M. Cardoso et al., “Strategies for serum chemokine/cytokine assessment as biomarkers of therapeutic response in HCV patients as a prototype to monitor immunotherapy of infectious diseases,” Antiviral Research, vol. 141, pp. 19–28, 2017. View at Publisher · View at Google Scholar · View at Scopus
  21. R. Villani, A. Facciorusso, F. Bellanti et al., “DAAs rapidly reduce inflammation but increase serum VEGF level: a rationale for tumor risk during anti-HCV treatment,” PLoS One, vol. 11, no. 12, article e0167934, 2016. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Mascia, S. Vita, P. Zuccalà et al., “Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral containing regimens with or without interferon,” PLoS One, vol. 12, no. 6, article e0179400, 2017. View at Publisher · View at Google Scholar · View at Scopus
  23. A. M. Tarragô, A. G. da Costa, J. P. D. Pimentel et al., “Combined impact of hepatitis C virus genotype 1 and interleukin-6 and tumor necrosis factor-α polymorphisms on serum levels of pro-inflammatory cytokines in Brazilian HCV-infected patients,” Human Immunology, vol. 75, no. 11, pp. 1075–1083, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. A. F. Carlin, P. Aristizabal, Q. Song et al., “Temporal dynamics of inflammatory cytokines/chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infection,” Hepatology, vol. 62, no. 4, pp. 1047–1058, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. L. Castéra, J. Vergniol, J. Foucher et al., “Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C,” Gastroenterology, vol. 128, no. 2, pp. 343–350, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. C. T. Wai, J. K. Greenson, R. J. Fontana et al., “A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C,” Hepatology, vol. 38, no. 2, pp. 518–526, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. R. K. Sterling, E. Lissen, N. Clumeck et al., “Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection,” Hepatology, vol. 43, no. 6, pp. 1317–1325, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. C. M. da Luz, M. S. P. Boyles, P. Falagan-Lotsch et al., “Poly-lactic acid nanoparticles (PLA-NP) promote physiological modifications in lung epithelial cells and are internalized by clathrin-coated pits and lipid rafts,” Journal of Nanobiotechnology, vol. 15, no. 1, p. 11, 2017. View at Publisher · View at Google Scholar · View at Scopus
  29. B. Abayli, A. Canataroglu, and H. Akkiz, “Serum profile of T helper 1 and T helper 2 cytokines in patients with chronic hepatitis C virus infection,” Turkish Journal of Gastroenterology, vol. 14, no. 1, pp. 7–11, 2003. View at Google Scholar
  30. N. A. Fierro, K. González-Aldaco, R. Torres-Valadez et al., “Spontaneous hepatitis C viral clearance and hepatitis C chronic infection are associated with distinct cytokine profiles in Mexican patients,” Memórias do Instituto Oswaldo Cruz, vol. 110, no. 2, pp. 267–271, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. B. Martin, N. Hennecke, V. Lohmann et al., “Restoration of HCV-specific CD8+ T cell function by interferon-free therapy,” Journal of Hepatology, vol. 61, no. 3, pp. 538–543, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. N. Zhai, X. Chi, T. Li et al., “Hepatitis C virus core protein triggers expansion and activation of CD4+CD25+ regulatory T cells in chronic hepatitis C patients,” Cellular & Molecular Immunology, vol. 12, no. 6, pp. 743–749, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. M. K. Jung and E. C. Shin, “Regulatory T cells in hepatitis B and C virus infections,” Immune Network, vol. 16, no. 6, pp. 330–336, 2016. View at Publisher · View at Google Scholar · View at Scopus
  34. P. Chalupa, A. Davidová, O. Beran et al., “Effect of antiviral treatment of chronic hepatitis C on the frequency of regulatory T cells, T-cell activation, and serum levels of TGF-beta,” APMIS, vol. 124, no. 8, pp. 711–718, 2016. View at Publisher · View at Google Scholar · View at Scopus
  35. J. A. Bachofner, P. V. Valli, A. Kröger et al., “Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index,” Liver International, vol. 37, no. 3, pp. 369–376, 2016. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Bernuth, E. Yagmur, D. Schuppan et al., “Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virus-infected patients treated with sofosbuvir,” Digestive and Liver Disease, vol. 48, no. 3, pp. 291–297, 2016. View at Publisher · View at Google Scholar · View at Scopus
  37. N. Ogasawara, M. Kobayashi, N. Akuta et al., “Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b,” Journal of Medical Virology, vol. 90, no. 2, pp. 313–319, 2018. View at Publisher · View at Google Scholar · View at Scopus
  38. Y. Backes, K. F. van der Sluijs, D. P. Mackie et al., “Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review,” Intensive Care Medicine, vol. 38, no. 9, pp. 1418–1428, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. M. L. Berres, B. Schlosser, T. Berg, C. Trautwein, and H. E. Wasmuth, “Soluble urokinase plasminogen activator receptor is associated with progressive liver fibrosis in hepatitis C infection,” Journal of Clinical Gastroenterology, vol. 46, no. 4, pp. 334–338, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. H. W. Zimmermann, A. Koch, S. Seidler, C. Trautwein, and F. Tacke, “Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis,” Liver International, vol. 32, no. 3, pp. 500–509, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. L. Garidou, S. Heydari, S. Gossa, and D. B. McGavern, “Therapeutic blockade of transforming growth factor beta fails to promote clearance of a persistent viral infection,” Journal of Virology, vol. 86, no. 13, pp. 7060–7071, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Kanzler, M. Baumann, P. Schirmacher et al., “Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-β,” Journal of Viral Hepatitis, vol. 8, no. 6, pp. 430–437, 2001. View at Publisher · View at Google Scholar · View at Scopus
  43. M. A. Burchill, J. A. Roby, N. Crochet et al., “Rapid reversal of innate immune dysregulation in blood of patients and livers of humanized mice with HCV following DAA therapy,” PLoS One, vol. 12, no. 10, article e0186213, 2017. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Majumdar, M. T. Kitson, and S. K. Roberts, “Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis,” Alimentary Pharmacology and Therapeutics, vol. 43, no. 12, pp. 1276–1292, 2016. View at Publisher · View at Google Scholar · View at Scopus